The Carlyle Group LP (NASDAQ:CG) [Trend Analysis] knocking active thrust in leading trading session, shares an increase of 0.60% to 16.75 with around 79947 shares have changed hands in this session. Carlyle Group LP (CG) declared that it is exploring a sale of nutritional-supplements maker Nature’s Bounty Co., whose brands include “MET-Rx” and “Pure Protein,” the Bloomberg declared citing people familiar with the matter.
The private equity firm has held talks with potential advisers about selling the U.S. company, formerly known as NBTY Inc. Nature’s Bounty could fetch as much as $6 billion in a sale, the report said.
While finding a buyer for the whole business is the preferred option, Carlyle also may decide to shop the international division separately, the report said. Holland & Barrett, based in the U.K. and founded in 1870, is the leading retailer of vitamins, minerals and herbal supplements in Europe, according to Nature’s Bounty’s website. The stock is going forward its fifty-two week low with 66.09% and lagging behind from its 52-week high price with -0.59%.
Similar, the positive performance for the quarter recorded as 10.42% and for the year was 28.89%, while the YTD performance remained at 9.18%. CG has Average True Range for 14 days of 0.46.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) [Trend Analysis] retains strong position in active trade, as shares scoring 15.24% to $3.38 in a active trade session, while looking at the shares volume, around 1.25 Million shares have changed hands in this session. Pernix Therapeutics Holdings, Inc. (PTX) reported that appointment of Ken Piña as Senior Vice President, General Counsel and Chief Compliance Officer. Mr. Piña will report directly to John Sedor, Chairman and Chief Executive Officer, and will serve as the Company’s senior in-house counsel, overseeing the legal and compliance area, and establishing legal and compliance strategies.
“Ken brings to Pernix extensive legal and life sciences experience with a notable record of achievement in developing and leading global legal and business initiatives for pharmaceutical companies,” said John Sedor, chairman and chief executive officer. “As our general counsel and chief compliance officer, Ken will be responsible for developing and managing our company’s legal and compliance strategies and related functional areas. He will also fill a vital role as a key member of Pernix’s Executive Leadership Team. We are delighted to welcome Ken to our company.” The firm has institutional ownership of 18.10%, while insider ownership included 2.10%. PTX attains analyst recommendation of 3.00 with week’s performance of 45.21%..